Communiqués de presse Archive - Page 3 of 24 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer

OSE Immunotherapeutics Launches Newsletter for Individual Shareholders

Half-Year Report on Liquidity Contract with Invest Securities

OSE Immunotherapeutics provides an update on ongoing proceedings

OSE Immunotherapeutics Publishes Letter to Shareholders

OSE Immunotherapeutics provides an update on ongoing proceedings

Précédent
1
2
3
4
5
6
7
8
9
…
24
Suivant